Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications

Autores
Cardinali, Daniel Pedro; Cano, Pilar; Jiménez Ortega, Vanesa; Esquifino, Ana I.
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities, and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep-wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequelae in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbidities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease, merits further investigation.
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Cátedra de Fisiologia; Argentina
Fil: Cano, Pilar. Universidad Complutense de Madrid; España
Fil: Jiménez Ortega, Vanesa. Universidad Complutense de Madrid; España
Fil: Esquifino, Ana I.. Universidad Complutense de Madrid; España
Materia
CIRCADIAN RHYTHMS
MELATONERGIC AGONISTS
MELATONIN
METABOLIC SYNDROME
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/191939
Acceder
id CONICETDig_76a8db6b08732d41f9d1bc8421991a1d
oai_identifier_str oai:ri.conicet.gov.ar:11336/191939
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implicationsCardinali, Daniel PedroCano, PilarJiménez Ortega, VanesaEsquifino, Ana I.CIRCADIAN RHYTHMSMELATONERGIC AGONISTSMELATONINMETABOLIC SYNDROMEhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities, and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep-wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequelae in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbidities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease, merits further investigation.Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Cátedra de Fisiologia; ArgentinaFil: Cano, Pilar. Universidad Complutense de Madrid; EspañaFil: Jiménez Ortega, Vanesa. Universidad Complutense de Madrid; EspañaFil: Esquifino, Ana I.. Universidad Complutense de Madrid; EspañaKarger2011-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/191939Cardinali, Daniel Pedro; Cano, Pilar; Jiménez Ortega, Vanesa; Esquifino, Ana I.; Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications; Karger; Neuroendocrinology; 93; 3; 4-2011; 133-1420028-38351423-0194CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.karger.com/Article/Abstract/324699info:eu-repo/semantics/altIdentifier/doi/10.1159/000324699info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:07:47Zoai:ri.conicet.gov.ar:11336/191939instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:07:47.664CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications
title Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications
spellingShingle Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications
Cardinali, Daniel Pedro
CIRCADIAN RHYTHMS
MELATONERGIC AGONISTS
MELATONIN
METABOLIC SYNDROME
title_short Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications
title_full Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications
title_fullStr Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications
title_full_unstemmed Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications
title_sort Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Cano, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Cano, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
author_role author
author2 Cano, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
author2_role author
author
author
dc.subject.none.fl_str_mv CIRCADIAN RHYTHMS
MELATONERGIC AGONISTS
MELATONIN
METABOLIC SYNDROME
topic CIRCADIAN RHYTHMS
MELATONERGIC AGONISTS
MELATONIN
METABOLIC SYNDROME
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities, and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep-wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequelae in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbidities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease, merits further investigation.
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Cátedra de Fisiologia; Argentina
Fil: Cano, Pilar. Universidad Complutense de Madrid; España
Fil: Jiménez Ortega, Vanesa. Universidad Complutense de Madrid; España
Fil: Esquifino, Ana I.. Universidad Complutense de Madrid; España
description Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities, and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep-wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequelae in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbidities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease, merits further investigation.
publishDate 2011
dc.date.none.fl_str_mv 2011-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/191939
Cardinali, Daniel Pedro; Cano, Pilar; Jiménez Ortega, Vanesa; Esquifino, Ana I.; Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications; Karger; Neuroendocrinology; 93; 3; 4-2011; 133-142
0028-3835
1423-0194
CONICET Digital
CONICET
url http://hdl.handle.net/11336/191939
identifier_str_mv Cardinali, Daniel Pedro; Cano, Pilar; Jiménez Ortega, Vanesa; Esquifino, Ana I.; Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications; Karger; Neuroendocrinology; 93; 3; 4-2011; 133-142
0028-3835
1423-0194
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.karger.com/Article/Abstract/324699
info:eu-repo/semantics/altIdentifier/doi/10.1159/000324699
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Karger
publisher.none.fl_str_mv Karger
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613941810954240
score 13.069144

Publicaciones similares